Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
24.96
+0.16 (0.65%)
Sep 28, 2026, 12:26 PM EDT - Market open
Stoke Therapeutics Employees
Stoke Therapeutics had 170 employees as of December 31, 2025. The number of employees increased by 42 or 32.81% compared to the previous year.
Employees
170
Change (1Y)
42
Growth (1Y)
32.81%
Revenue / Employee
$162,282
Profits / Employee
-$1,222,959
Market Cap
1.61B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 170 | 42 | 32.81% |
| Dec 31, 2024 | 128 | 18 | 16.36% |
| Dec 31, 2023 | 110 | -7 | -5.98% |
| Dec 31, 2022 | 117 | 15 | 14.71% |
| Dec 31, 2021 | 102 | 23 | 29.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Immunocore Holdings | 524 |
| Intellia Therapeutics | 377 |
| Syndax Pharmaceuticals | 298 |
| Innoviva | 159 |
| Absci | 140 |
| AnaptysBio | 104 |
| Nanobiotix | 100 |
| Taysha Gene Therapies | 99 |
STOK News
- 4 days ago - Stoke Therapeutics names Bo Cumbo to board of directors - TheFly
- 4 days ago - Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization - Business Wire
- 11 days ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 18 days ago - Stoke Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 24 days ago - Stoke Therapeutics, Biogen present long-term data on Zorevunersen - TheFly
- 24 days ago - Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - Business Wire
- 26 days ago - Stoke Therapeutics to Present at the Cantor Global Healthcare Conference - Business Wire
- 27 days ago - Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate - TheFly